Ergoteles’s Harmony Biosciences HRMY Stock Holding History

Ergoteles’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-105,555	Closed	-$3.82M	–	912
2020 Q4	$3.82M	Buy	+105,555	New	+$4.26M	0.13%	177

Other funds holding HRMY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Ergoteles's HRMY Position: Q1 2021 in Review

Ergoteles sold out of Harmony Biosciences (HRMY) in Q1 2021, closing a stake of 105,555 shares — an estimated $3.82M sold.

Ergoteles first reported a position in HRMY in Q4 2020 and held it in 1 quarter. The position peaked at $3.82M in Q4 2020. 57 funds tracked by Wall St. Rank hold HRMY as of Q1 2021.

Ergoteles reported no remaining Harmony Biosciences position as of Q1 2021 after selling out during the quarter.
Ergoteles sold 105,555 Harmony Biosciences shares in Q1 2021, an estimated $3.82M.
Ergoteles first reported a position in Harmony Biosciences in Q4 2020 and held it in 1 quarter.
Ergoteles's Harmony Biosciences position peaked at $3.82M in Q4 2020.
57 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2021.

Based on Ergoteles's 13F filing for Q1 2021, filed 12 May 2021.